世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

欧州の血漿市場予測 2020-2028年

EUROPE BLOOD PLASMA MARKET FORECAST 2020-2028

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2020年4月US$1,250
シングルユーザライセンス(印刷不可PDF)
175

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

サマリー

この調査レポートは欧州の血漿市場を分析・予測したInkwood Researchの市場調査報告書です。

Overview

KEY FINDINGS

The Europe blood plasma market is predicted to record growth, at a CAGR of 6.39% during the forecast period. The growing geriatric population and the increasing cases of immunodeficiency diseases, are the major drivers of market growth.

MARKET INSIGHTS

The Europe blood plasma market growth assessment involves the market analysis of Russia, Germany, the United Kingdom, Italy, Belgium, Poland, France, and the rest of Europe. Germany was one of the major countries to record the highest rate of blood plasma donations through apheresis. There has been an increasing number of sports injuries that affect areas like joints or tendons. Such factors have resulted in the widespread use of blood plasma procedure due to its varied benefits. There is an increasing prevalence of osteoarthritis in Italy, leading to increased demands for blood plasma. Also, the use of polyvalent immunoglobulins that are administered through the subcutaneous route has grown over the years as a result of increasing preference for self-infusion by patients. In Russia, the rising aging population, and the resultant demand for a strong healthcare system, are set to boost market growth. The countries in the rest of Europe segment make use of blood plasma treatment for cosmetic and sports medicine treatment.

COMPETITIVE INSIGHTS

Some of the renowned companies in the market include, Grifols, Kedrion Biopharma Inc, Octapharma, Biotest AG, Cerus Corporation (Cerus), etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments



目次

Table of Contents

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS: BLOOD MARKET
3.2. MARKET DEFINITION
3.3. KEY DRIVERS
3.3.1. WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
3.3.2. GROWING USAGE OF ALBUMIN IN OTHER THERAPEUTIC AREAS
3.3.3. GROWING GERIATRIC POPULATION IN EUROPE
3.3.4. SPREAD OF COVID-19 IN EUROPEAN REGION
3.3.5. INCREASE IN THE PATIENT POOL FOR HEMOPHILIA TREATMENT
3.3.6. GROWTH IN AWARENESS ABOUT BLOOD AND PLASMA DONATION
3.3.7. RISE IN OCCURRENCE OF SPORTS INJURIES
3.4. KEY RESTRAINTS
3.4.1. HIGH COST OF BLOOD PLASMA TREATMENTS
3.4.2. INCREASING USAGE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
3.4.3. ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
3.4.4. STRINGENT REGULATIONS
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. PLASMA THERAPEUTICS REGULATION
4.6. MARKET TRENDS
4.7. CLINICAL GUIDELINES
5. MARKET BY BLOOD PLASMA DERIVATIVES
5.1. IMMUNOGLOBULIN
5.1.1. INTRAVENOUS IMMUNOGLOBULIN
5.1.2. SUBCUTANEOUS IMMUNOGLOBULIN
5.1.3. OTHER IMMUNOGLOBULIN TYPE
5.2. ALBUMIN
5.3. HYPERIMMUNE
5.4. COAGULATION FACTOR CONCENTRATES
5.5. OTHER PLASMA FRACTIONATION PRODUCTS
6. MARKET BY THERAPEUTIC INDICATION
6.1. NEUROLOGY
6.2. IMMUNOLOGY
6.3. ONCOLOGY
6.4. TRANSPLANTATION
6.5. HEMATOLOGY
6.6. RHEUMATOLOGY
6.7. PULMONOLOGY
6.8. OTHER THERAPEUTIC INDICATION
7. MARKET BY DISORDER
7.1. IMMUNODEFICIENCY DISEASES
7.2. HYPOGAMMAGLOBULINEMIA
7.3. HEMOPHILIA
7.4. VON WILLEBRAND DISEASE (VWD)
7.5. OTHER DISORDER
8. MARKET BY END-USER
8.1. HOSPITALS AND CLINICS
8.2. RESEARCH LABORATORIES
8.3. ACADEMIC INSTITUTIONS
9. GEOGRAPHICAL ANALYSIS
9.1. EUROPE
9.1.1. UNITED KINGDOM
9.1.2. GERMANY
9.1.3. FRANCE
9.1.4. ITALY
9.1.5. RUSSIA
9.1.6. BELGIUM
9.1.7. POLAND
9.1.8. REST OF EUROPE
10. COMPANY PROFILES
10.1. ADMA BIOLOGICS
10.2. ARTHREX
10.3. BIO PRODUCTS LABORATORY
10.4. BAXTER INTERNATIONAL
10.5. BIOTEST AG
10.6. CERUS CORPORATION (CERUS)
10.7. CHINA BIOLOGIC PRODUCTS
10.8. CSL LIMITED
10.9. FUSION HEALTH CARE
10.10. GREEN CROSS HOLDINGS CORPORATION
10.11. GRIFOLS
10.12. LFB
10.13. OCTAPHARMA
10.14. TAKEDA PHARMACEUTICAL COMPANY
10.15. KEDRION BIOPHARMA INC

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - BLOOD PLASMA
TABLE 2: EUROPE BLOOD PLASMA MARKET, BY BLOOD PLASMA DERIVATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 3: EUROPE BLOOD PLASMA MARKET, BY BLOOD PLASMA DERIVATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 4: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 6: EUROPE BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: EUROPE BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 8: EUROPE BLOOD PLASMA MARKET, BY DISORDER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: EUROPE BLOOD PLASMA MARKET, BY DISORDER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: EUROPE BLOOD PLASMA MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: EUROPE BLOOD PLASMA MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 12: EUROPE BLOOD PLASMA MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: EUROPE BLOOD PLASMA MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

Companies Mentioned

LIST OF FIGURES
FIGURE 1: KEY INVESTMENT INSIGHTS
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: VENDOR LANDSCAPE
FIGURE 5: EUROPE BLOOD PLASMA MARKET, GROWTH POTENTIAL, BY BLOOD PLASMA DERIVATIVES, IN 2019
FIGURE 6: EUROPE BLOOD PLASMA MARKET, BY IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
FIGURE 7: EUROPE IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
FIGURE 8: EUROPE IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
FIGURE 9: EUROPE IMMUNOGLOBULIN MARKET, BY OTHER IMMUNOGLOBULIN TYPE, 2020-2028 (IN $ MILLION)
FIGURE 10: EUROPE BLOOD PLASMA MARKET, BY ALBUMIN, 2020-2028 (IN $ MILLION)
FIGURE 11: EUROPE BLOOD PLASMA MARKET, BY HYPERIMMUNE, 2020-2028 (IN $ MILLION)
FIGURE 12: EUROPE BLOOD PLASMA MARKET, BY COAGULATION FACTOR CONCENTRATES, 2020-2028 (IN $ MILLION)
FIGURE 13: EUROPE BLOOD PLASMA MARKET, BY OTHER PLASMA FRACTIONATION PRODUCTS, 2020-2028 (IN $ MILLION)
FIGURE 14: EUROPE BLOOD PLASMA MARKET, GROWTH POTENTIAL, BY THERAPEUTIC INDICATION, IN 2019
FIGURE 15: EUROPE BLOOD PLASMA MARKET, BY NEUROLOGY, 2020-2028 (IN $ MILLION)
FIGURE 16: EUROPE BLOOD PLASMA MARKET, BY IMMUNOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 17: EUROPE BLOOD PLASMA MARKET, BY ONCOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 18: EUROPE BLOOD PLASMA MARKET, BY TRANSPLANTATION, 2020-2028 (IN $ MILLION)
FIGURE 19: EUROPE BLOOD PLASMA MARKET, BY HEMATOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 20: EUROPE BLOOD PLASMA MARKET, BY RHEUMATOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 21: EUROPE BLOOD PLASMA MARKET, BY PULMONOLOGY, 2020-2028 (IN $ MILLION)
FIGURE 22: EUROPE BLOOD PLASMA MARKET, BY OTHER THERAPEUTIC INDICATION, 2020-2028 (IN $ MILLION)
FIGURE 23: EUROPE BLOOD PLASMA MARKET, GROWTH POTENTIAL, BY DISORDER, IN 2019
FIGURE 24: EUROPE BLOOD PLASMA MARKET, BY IMMUNODEFICIENCY DISEASES, 2020-2028 (IN $ MILLION)
FIGURE 25: EUROPE BLOOD PLASMA MARKET, BY HYPOGAMMAGLOBULINEMIA, 2020-2028 (IN $ MILLION)
FIGURE 26: EUROPE BLOOD PLASMA MARKET, BY HEMOPHILIA, 2020-2028 (IN $ MILLION)
FIGURE 27: EUROPE BLOOD PLASMA MARKET, BY VON WILLEBRAND DISEASE (VWD), 2020-2028 (IN $ MILLION)
FIGURE 28: EUROPE BLOOD PLASMA MARKET, BY OTHER DISORDER, 2020-2028 (IN $ MILLION)
FIGURE 29: EUROPE BLOOD PLASMA MARKET, GROWTH POTENTIAL, BY END-USER, IN 2019
FIGURE 30: EUROPE BLOOD PLASMA MARKET, BY HOSPITALS AND CLINICS, 2020-2028 (IN $ MILLION)
FIGURE 31: EUROPE BLOOD PLASMA MARKET, BY RESEARCH LABORATORIES, 2020-2028 (IN $ MILLION)
FIGURE 32: EUROPE BLOOD PLASMA MARKET, BY ACADEMIC INSTITUTIONS, 2020-2028 (IN $ MILLION)
FIGURE 33: EUROPE BLOOD PLASMA MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 34: UNITED KINGDOM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 35: GERMANY BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 36: FRANCE BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 37: ITALY BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 38: RUSSIA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 39: BELGIUM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 40: POLAND BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
FIGURE 41: REST OF EUROPE BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る